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HYPEREKPLEXIA CAUSED BY DOMINANT-
NEGATIVESUPPRESSIONOFGLYRA1FUNCTION
Hyperekplexia (HE; startle disease; OMIM
#149400) is a rare inheritable neurologic disorder
characterized by an exaggerated response to sud-
den stimuli, muscular rigidity, and hyperreflexia,
leading to chronic injuries due to unprotected
falls. All symptoms are present at birth but grad-
ually decline during the first year of life, although
an exaggerated startle response remains during
adulthood.1
Dysfunctional inhibitory neurotransmission by
glycine (Gly) plays a central role in HE pathogene-
sis. All patients with HE carry mutations in genes
encoding either for 1 (GLYRA1) or  (GLYRB)
Gly receptor subunits, presynaptic Gly transporters
(SLC6A5), or proteins involved in Gly receptor
(GLYR) clustering, such as gephyrin (GPHN) and
collybistin (ARHGEF9).1,2
GLYRA1 subunits interact in a heteropentameric
complex with homologous  subunits (312).
Each subunit comprises an extracellular
N-terminus, four -helical transmembrane seg-
ments (TM1 to TM4), and an extracellular C-termi-
nus; TM2 segments are thought to align the Cl

selective pore.1
Different GLYRA1 missense and nonsense mu-
tations have been associated with autosomal
dominant, autosomal recessive, and sporadic
forms of HE. Missense mutations may show in-
complete penetrance and impair channel gating,
trafficking, and stability.3 Nonsense mutations
have been reported only in recessive cases, in
compound heterozygosity with a missense muta-
tion, or in homozygosity in the offspring of con-
sanguineous nonaffected parents and appear
unable to cause the startle phenotype in heterozy-
gosis.4,5 A recessive form of HE linked to a
GLYRA1 null allele has been described,6 suggest-
ing a nonpathogenic role for haplotype
insufficiency.
In this study, we investigated the functional con-
sequences of a de novo GLYRA1 heterozygous non-
sense mutation (S296X) in a 1-year-old boy. The
patient was born at term after an uneventful preg-
nancy and delivery; after 1 week, he had high-
frequency attacks of generalized stiffness appearing
spontaneously or elicited by sensorial stimuli; at-
tacks were not associated with EEG alterations or
unconsciousness. Symptoms were successfully
treated with valproic acid. Drug treatment was sus-
pended after 6 months; since then, the baby shows
normal psychomotor development and is symptom
free. Neurologic evaluation and clinical history of
the parents were unremarkable.
Molecular analysis of the GLYRA1 gene re-
vealed a heterozygous point mutation in exon 7
(nt c1267a) in the patient, but not in his unaf-
fected parents or in 50 unrelated controls (see
methods on the Neurology Web site at www.
neurology.org for further experimental details).
The mutation truncated the protein at codon 296
(S296X), within the TM3 domain (figure, A).
The functional consequences of this mutation
were evaluated by biochemical and electrophysi-
ologic techniques upon heterologous expression
in HEK-293 cells. In Western blots from total cell
lysates and plasma-membrane fractions from
GLYRA1-transfected cells, the mAb4a antibody
revealed a 48-kd band; by contrast, a 34-kd band,
corresponding to truncated subunits, was ob-
served in GLYRA1 S296X–transfected cells.
When the two subunits were coexpressed, both
total lysates (data not shown) and membrane
fractions showed a reduction in the 48-kd band
intensity, whereas that of the 34-kd band was un-
changed (figure, B).
In whole-cell path-clamp electrophysiologic ex-
periments, cells expressing GLYRA1 subunits ex-
hibited large Gly-gated Cl currents; by contrast, in
GLYRA1 S296X–transfected cells, Gly failed to
elicit Cl currents (figure, C). In cells coexpressing
GLYRA1 and GLYRA1 S296X subunits, Gly-gated
currents were smaller when compared with
GLYRA1-expressing cells (figure, C and D), with no
significant change in Gly apparent affinity between
the two groups of cells.
These results are suggestive of a significant inter-
action between wild-type and mutant GLYRA1
subunits, leading to a dominant-negative effect.
Ligand-gated channels assemble cotranslationally in
the endoplasmic reticulum (ER), where they un-
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dergo folding and post-translational modifications.
S296X GLYRA1 subunits lack the M3-M4 loop reg-
ulating GlyR membrane concentration,7 but retain
two disulfide bonds (C138-C152, C198-C209),
which stabilize the N-terminal region and allow the
channel to exit from the ER. Therefore, S296X
GLYRA1 subunits likely retain the molecular deter-
minants allowing oligomerization with wild-type
GLYRA1 subunits; this interaction suppresses
GLYRA1 membrane expression and function.
Two different GLYRA1 nonsense mutations
(Y202X5 and R344X4) have been reported in re-
cessive forms of HE, suggesting that both of these
mutant alleles failed to exert a clinically signifi-
cant dominant effect. The Y202X mutation was
found in a child of consanguineous parents,
whereas the R344X mutation was found in com-
pound heterozygosity with a missense mutation
(W96C). Truncated GLYRA1 Y202X subunits
lack some of the molecular determinants required
to assume a correct topology and are unlikely to
assemble into oligomers and exit from the ER.
Conversely, the R344X mutation lies in the large
positively charged M3-M4 intracellular loop; neu-
tralization of all positive charges within this re-
gion affects subunit topology.7
In conclusion, biochemical and electrophysi-
ologic analyses suggest that GLYRA1 S296X sub-
units impair GLYRA1 subunit function, thus
representing the first description of a GLYRA1 het-
Figure Predicted topology and functional consequences of GLYRA1 subunits carrying the S296X mutation
(A) Presumed topologic arrangement of wild-type and mutant GLYRA1 receptor subunits. (B) Western blot experiment in purified
plasma membrane fractions from HEK-293 cells. Bands of 48 kd and 34 kd, corresponding to GLYRA1 and GLYRA1 S296X
subunits, were revealed by the mAb4a monoclonal antibody in streptavidin-isolated biotinylated plasma membrane proteins from
HEK-293 cells transfected with GLYRA1, GLYRA1 S296X, or both cDNAs, as indicated. The optical density of the 48-kd band in
each group, normalized to the values obtained in HEK-293 cells transfected with 2 g of cDNA, was 0.63 0.23 (GLYRA1, 1 g),
1.00 0.19 (GLYRA1, 2 g), 0.22 0.11 (GLYRA1GLYRA1 S296X, 1 g 1 g), and 0.32 023 (GLYRA1GLYRA1
S296X, 2 g 2 g). Data are the mean SEM from four separate experiments. (C) Representative whole-cell currents evoked by
increasing concentration of glycine (Gly) in HEK-293 cells expressing GLYRA1, GLYRA1 S296X, or both subunits. The holding
potential was60 mV. The duration of Gly perfusion is indicated by the length of the bars on top of each current trace.
Concentration-response curves for Gly (0.3 M to 30 mM) were obtained for each group by averaging from different cells the peak
inward current values evoked by each Gly concentration, after normalization to the maximal value. The data from the two groups
(cells expressing GLYRA1, or GLYRA1GLYRA1 S296X subunits) were then fitted to the following form of the Hill equation y
ymax ([Gly]nH/[Gly]nH EC50nH). EC50 and nH values were 56.8 4.2 M and 1.2 0.1 for GLYRA1-expressing cells (0.2 g) and
40.3 1.3 M and 1.5 0.1 for GLYRA1GLYRA1 S296X–expressing cells (0.2 g 0.2 g) (n 12 different cells per group).
(D) Quantification of the Cl current density induced by 3mMGly in HEK-293 cells transfected with GLYRA1 (0.2 g) or GLYRA1
S296X (0.2 g) cDNAs, alone or together as indicated. Current densities were calculated in each cell by dividing bymembrane
capacitance the peak current value evoked by 3mMGly. At least 30 cells for each groupwere recorded from four different
transfections. *Value significantly different from controls. **Value significantly different fromGLYRA1-transfected cells. CTL control.
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erozygous nonsense mutation causing the startle
phenotype by a dominant-negative mechanism.
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SPONTANEOUS TIBIALIS ANTERIOR TENDON
RUPTURE: A RARE CAUSE OF FOOT DROP
Tibialis anterior tendon (TAT) rupture is an un-
common musculoskeletal condition that is rarely
encountered by neurologists.1 Most patients
present with foot drop and pain and may be mis-
diagnosed as a peroneal mononeuropathy or L5
radiculopathy. Clinical recognition and distinc-
tion of this entity from other causes of foot drop
are important for neurologists. We describe two
patients with spontaneous TAT ruptures who
presented for neurologic consultation for sus-
pected peroneal neuropathies.
Case 1. A 73-year-old man with a history of atrial
fibrillation and hypertension was walking on his
treadmill when he noted a painless “pop” in his
right anterior ankle followed by “flopping” of
his foot. A few days later, he noted swelling on
the anterior aspect of his ankle and difficulty dor-
siflexing his right foot. He denied back pain and
bladder dysfunction. Neurologic examination
demonstrated mild weakness in right ankle dorsi-
flexion with normal strength in all other muscles
including toe extension and ankle eversion and
inversion. There was swelling on the anterior sur-
face of the right ankle (figure, A). The extensor
hallucis longus and digitorum longus tendons
were intact, but the TAT was not palpable at its
insertion site.
Nerve conduction studies, including right pero-
neal motor, were normal for age. Needle EMG dem-
onstrated residual of an old right L5 radiculopathy,
but examination of the TA muscle demonstrated a
normal recruitment pattern of motor unit poten-
tials. MRI of the right ankle demonstrated a com-
plete tear of the TAT at the level of the extensor
retinaculum. A small fluid collection was seen in the
region of the tendon sheath. (figure, B) The patient
elected conservative therapy.
Case 2. A 79-year-old woman with hypertension, hy-
perlipidemia, and coronary artery disease was evalu-
ated for an 8-week history of a left foot drop. The
precise onset of the foot drop was not known. She de-
nied precipitating trauma, sudden foot or back pain,
progressive weakness, and numbness. Examination
demonstrated weakness of the left TA muscle with
normal strength in all other lower extremity muscles
and a steppage gait. Reflexes and sensory examination
were normal. Orthopedic consultation noted retrac-
tion of the left TAT proximal to the ankle.
Nerve conduction studies were normal. Needle
EMG revealed poor activation but an otherwise
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normal recruitment pattern in the left TA muscle.
Other muscles examined were normal. MRI of the
leg revealed retraction and thickening of the left
TAT at the level of the tibiotalar joint beyond
which it was noted to terminate abruptly (figure, C
through E). Due to the chronicity of the rupture, she
was treated conservatively.
Discussion. Rupture of the TAT is an uncommon
musculoskeletal condition that presents as foot drop
but is rarely encountered by neurologists.1 Most cases
are caused by direct or indirect foot trauma. Diabetes,
systemic lupus erythematosus, hyperparathyroidism,
psoriasis, and gout may produce tenosynovitis and are
other associated etiologies.1-4 Spontaneous TAT rup-
ture is rare and may be the most difficult form to dis-
tinguish from a neurogenic etiology of foot drop.4,5
Themost prominent clinical feature of TAT rupture is
weakness of foot dorsiflexion. However, increased
compensatory action of the extensor hallucis longus
and extensor digitorum longus may minimize the de-
gree of weakness and make identification more diffi-
cult.5,6 The absence of toe extensor, foot eversion, and
hip abductionweakness helps to distinguish TAT rup-
ture from other neuromuscular causes of foot drop,
such as peroneal neuropathy, lumbosacral plexopa-
thy, or L5 radiculopathy. The pathognomonic sign of
TAT rupture is the presence of the retracted tendon,
which produces a palpable defect or swelling along the
dorsum of the ankle (figure). Normal findings on nee-
dle EMG of the TA muscle is useful to distinguish
TAT rupture from neuromuscular causes of foot drop
Figure Cases 1 and 2
(A) Swelling on the dorsum of
the ankle (arrowhead) due to
a retracted tibialis anterior
tendon 3 weeks following
rupture in Patient 1. (B) MRI
of right ankle demonstrating
fluid collection (arrow) in the
region of the anterior tibialis
tendon sheath. (C) Axial T1-
weighted MRI across the
proximal third of the leg
showing the fatty
replacement of the left
tibialis anterior muscle as
compared with the normal
appearing tibialis anterior on
the right in Patient 2. (D) Axial
T2-weighted fat saturation
MRI sequences across the
distal third of the leg showing
the thickened retracted
tibialis anterior tendon on the
left as compared with the
normal tibialis anterior
tendon on the right. (E) Axial
T2-weighted fat saturation
MRI sequences across the
ankle showing the normal
tibialis anterior tendon on the
right as compared with
absence of the tendon on the
left.
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where reduction in the recruitment of motor units
would be seen.MRI of the ankle is the imagingmodal-
ity of choice to confirm TAT rupture by identifying
partial or complete ruptures of the tendon.7
No consensus on conservative management vs
surgical repair of TAT rupture has been established.
In cases of acute ruptures or in young, active indi-
viduals, surgical repair may provide better func-
tional outcome. Potential long-term complications
if the diagnosis is missed include pain from the re-
tracted stump, neuroma, and extensor substitution
with clawing, flat foot, weakness, and heel cord
contractures.6
In conclusion, TAT rupture should be considered
in the differential diagnosis of foot drop. The identifi-
cation of a swelling on the ankle and normal electrodi-
agnostic testing in the context of clinical weakness are
clues to help in suspecting the diagnosis, and MRI of
the lower leg is necessary for confirmation.
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MUTATIONS IN VAPB ARE NOT ASSOCIATED
WITH SPORADIC ALS
ALS is the third most common adult-onset neurode-
generative disorder. Themajority of cases are sporadic
(SALS), whereas 5 to 10% are familial (FALS). There
are 13 known loci, with causative genes identified at
seven, including superoxide dismutase 1 (SOD1) and
angiogenin (ANG).1,2 Recently, mutations in vesicle-
associatedmembrane protein (VAMP) associated pro-
tein B (VAPB) have been associated with autosomal
dominant, adult-onset ALS8.3
VAPB is ubiquitously expressed, and evidence sug-
gests that it plays a role in vesicle trafficking.4 As
VAPBwas the only gene, other than SOD1, known to
cause adult-onset, autosomal dominant ALS, we un-
dertook a mutation screening strategy to establish the
contribution ofVAPBmutations in a large cohort of
ALS patients. Although it is appreciated that muta-
tions would be most likely to be found in familial
cases, mutations in SOD1 and more recently ANG
have been reported in SALS. Therefore, both FALS
and SALS cases were screened for mutations in
VAPB.
Methods. DNA was extracted from 301 cases of
ALS (23 FALS in whom SOD1 mutations had been
excluded and 278 SALS cases), originating from 86
postmortem CNS samples in the Sheffield Brain Tis-
sue Bank and 215 blood samples in our DNA data-
base; all were United Kingdom (UK) cases of
Caucasian ethnicity. All patients had definite or
probable ALS by revised El Escorial criteria.5 Con-
trols samples were obtained from either our local
DNA database or from healthy donors at the Shef-
field Blood Transfusion Service after appropriate
ethics approval and donor consent. All individuals
were neurologically normal and older than 50 years
of age; ethnicity for all cases was UK Caucasian.
All six exons of the VAPB gene were amplified
using intronic primers to ensure all coding regions
and splice sites were sequenced (table). PCR prod-
ucts were purified using ExoSAP-IT (USB/Amer-
sham Biosciences) and then bidirectionally
sequenced using ABI PRISM BigDye Terminator
v3.1 cycle sequencing kit (ABI). Samples were run
on an ABI 3730 capillary analyzer (Applied
Biosystems).
To determine whether the deletion of Ser159 was
present in the normal population, restriction en-
zyme digestion usingMboII was used to screen con-
trols. The frequency of the C to T polymorphism 35
bp downstream of exon 3 in intron 3 was screened
by digestion with MaeIII (Roche). Direct sequenc-
ing was used to screen controls for the G to A nucle-
otide substitution 4 bp upstream of exon 6.
Results.Mutation screening of the entire coding re-
gion and intron/exon boundaries in 301 ALS cases
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identified a 3-bp deletion (del 746-8 TCT) in exon 5,
resulting in the loss of Ser159 in two SALS cases.
Screening of 120 controls using MboII restriction
enzyme digests identified a further two individuals
with this deletion, suggesting this change is a poly-
morphism found in the general population.
Three nucleotide substitutions were also found.
The first, C763T, was novel but did not alter the
amino acid. The second, a G to A 4 bp upstream of
exon 6, was only found in one SALS case and not in
111 controls. This change was not predicted to alter
the splice site (www.fruitfly.org/seq_tools/splice). Fi-
nally, a C to T polymorphismwas found 35 bp down-
streamof exon 3. Therewere no significant differences
between the polymorphic frequencies in ALS and con-
trols (n  107) (ALS: C  60.0%, T  40.0%; con-
trols: C 64.5%, T 35.5%; 2: p 0.24).
Discussion. Screening of VAPB in 278 SALS cases
has identified no clear pathogenic mutations associ-
ated with the disease. This study provides robust
evidence that mutations in VAPB are not associated
with SALS in the UK, although it is not possible to
rule out that the mutation upstream of exon 6 may
produce an abnormal transcript. VAPB mutations
were not found in any of the non-SOD1 FALS cases
screened, although due to the small sample size and
apparent rarity ofVAPBmutations, it cannot be ruled
out thatVAPB is a rare cause of FALS in the UK.
The initial P56S mutation was identified in seven
Brazilian families of either African or Caucasian de-
scent with varying clinical phenotypes.3 However,
further studies have shown that this mutation is due
to a common founder 23 generations previously,
when Brazil was colonized by the Portuguese.6
More recently, a study concluded that VAPB muta-
tions were not a common cause of SALS in Italy.7
Taking these studies into consideration, it is sug-
gested that VAPB mutations do not significantly
contribute to the genetic causes of SALS in the UK
and Northern Europe. However, further studies of
the Portuguese ALS population may identify ances-
tors of the common founder, and it is possible that
VAPB mutations may contribute to SALS in other
populations.
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